Cancer Medicines Responding to Both Cytotoxic and Hormonal Therapies - Latin American Oncology Therapeutics Markets.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49422) has announces the addition of Frost & Sullivan Report Latin American Oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. Markets to their offering. This study provides a comprehensive overview of the commercial market for lung, breast and colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. medicines responding to both cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic and hormonal therapies Hormonal therapyUse of hormone medications to inhibit menstruation and relieve the symptoms of endometriosis. Mentioned in: Endometriosis . Researched countries are Mexico, Brazil, and Argentina. Included are competitive profiles, distribution network discussions, pricing analysis, drug pipelines, regulatory issues, major market drivers and restraints, market shares by revenue and commercial forecasts from 2005-2010. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: * Oncology products combating lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. * Oncology products combating breast cancer * Oncology products combating colorectal cancer Technologies The following technologies are covered in this research: Cytotoxic Hormonal Market Overview New Treatments for Cancer to Emerge in Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. Oncology therapy products markets are undergoing dynamic development in many countries around the world. New molecules are constantly being researched and launched by large pharmaceutical companies aiming to develop their portfolios and replace expired drugs. However, advances first introduced in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Europe reach Latin America with some delay. "Nevertheless, as the disease's rate increases steadily in this region and companies become more global everyday, this time gap will progressively reduce," says the analyst of the study. "In the long term, if the political and economic situation continues to improve, those advances will reach Latin America almost simultaneously as the rest of the world." Until 2000, cancer treatment (diagnosis, surgery, chemotherapy, radiotherapy radiotherapy /ra·dio·ther·a·py/ (-ther´ah-pe) treatment of disease by means of ionizing radiation; tissue may be exposed to a beam of radiation, or a radioactive element may be contained in devices (e.g. , and palliative care palliative care (paˑ·lē·ā·tiv kerˑ), n an approach to health care that is concerned primarily with attending to physical and emotional comfort rather ) was available almost exclusively only in hospitals based in big Latin American cities. As a result, a large number of people, especially inhabitants
The game is based loosely on the concepts from SameGame. from farther regions, still have no access to cancer diagnosis and treatment. This uncovered population can also easily cause an under-estimation of cancer incidence in Latin America. Over the past five years, however, governments are making efforts to expand the coverage of treatment to this population thus expanding the horizons of oncology therapeutics markets. Pharmaceutical Companies' Extensive Product Lines to Boost Latin American Oncology Markets Latin America offers a diverse landscape in terms of market development for oncology products. Most tier 1 pharmaceutical companies have subsidiaries in important countries in this region and compete for price and qualitative differentiation. This competition is also extended toward local companies selling copies of patent-expired products. Due to their competitive edge in terms of price, firms selling generics are well positioned with regard to public sector purchases. The Latin American oncology market is growing - both the quantity and variety of the compositions in the pharmaceutical company's drug pipelines contribute to this. Due to its size and demographic attributes, this region is a permanent receptor of new drugs. A direct result is that multinational companies are focusing more than ever on R&D activities. Even though regulations for the approval of new products are difficult to comply with, for the medium term companies become successful at introducing their new discoveries into this market. "Successful R&D performances become pharmaceutical companies' main assets," explains the analyst. "Their commercial interests mainly consist of generating the necessary resources to feed R&D activities and generate new and effective drugs and this is likely to boost the growth of the oncology therapeutics market in this region." Content Outline: * 1. Latin American Market Introduction and Executive Summary * 2. Brazil Oncology Products Cytotoxic and Hormonal Therapies * 3. Mexico Oncology Products Cytotoxic and Hormonal Therapies * 4. Argentina Oncology Products - Cytotoxic and Hormonal Therapies For more information visit http://www.researchandmarkets.com/reports/c49422 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion